v3.26.1
SEGMENT REPORTING (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2024
IfrsStatementLineItems [Line Items]      
Segment revenues $ 97
Segment expenses      
Research and development 2,801 3,129 12,535
General and administrative expenses 20,199 4,254 5,664
Depreciation and amortization expense 1,014 (86) (242)
Segment loss from operations (23,096) (7,418) (18,253)
Change in fair value of warrant liability 2,883 (388) 6,868
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone 11,305
Change in fair value of put rights, net of redemptions 5,959
Loss on revaluation of digital assets 1,411
Loss on revaluation of digital asset receivables 1,497
Realized loss on sale of digital assets 1,700
Realized loss on novation of digital asset receivables 676    
Gain on settlement with Parexel - iOx CRO (946)
Loss on Registered Direct Offering 2,432
Offering costs 662
Impairment loss - iOx IPR&D (57,890)
Impairment loss - Tarus IPR&D (23,615)
Impairment loss - Stimunity (1,002)
Impairment loss - Saugatuck (178)
Commitment fee under Committed Purchase Agreement 839
Gain on dissolution of investment in associate 27
Gain from sale of investment in public company 725
Impairment loss - investment in Compedica 4,804
Loss on revaluation of investment in Compedica 182
Change in fair value of TON payable to settle put rights exercised 51
Gain on settlement of TON payable 336
Loss on settlement of put right liability 916
Loss on extinguishment of debt 582    
Gain on forgiveness of loan interest 255
Share of losses from equity method investment 44 233
Digital Compute [Member]      
IfrsStatementLineItems [Line Items]      
Segment revenues 97    
Segment expenses      
Research and development    
General and administrative expenses 16,344    
Depreciation and amortization expense 193    
Segment loss from operations (16,440)    
Change in fair value of warrant liability 1,097    
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone    
Change in fair value of put rights, net of redemptions (5,959)    
Loss on revaluation of digital assets (1,411)    
Loss on revaluation of digital asset receivables (2,349)    
Realized loss on sale of digital assets (1,700)    
Realized loss on novation of digital asset receivables 676    
Gain on settlement with Parexel - iOx CRO    
Loss on Registered Direct Offering    
Offering costs    
Impairment loss - iOx IPR&D    
Impairment loss - Tarus IPR&D    
Impairment loss - Stimunity    
Impairment loss - Saugatuck    
Commitment fee under Committed Purchase Agreement    
Gain on dissolution of investment in associate    
Gain from sale of investment in public company    
Impairment loss - investment in Compedica    
Loss on revaluation of investment in Compedica (182)    
Change in fair value of TON payable to settle put rights exercised 51    
Gain on settlement of TON payable 336    
Loss on settlement of put right liability (916)    
Foreign exchange transaction (loss) gain 4    
Interest (expense) income, net (1,022)    
Loss on extinguishment of debt (582)    
Gain on forgiveness of loan interest 837    
Share of losses from equity method investment    
Segment loss before benefit for income taxes (28,912)    
Income tax benefit    
Segment net loss (28,912)    
Immuno Oncology [Member]      
IfrsStatementLineItems [Line Items]      
Segment revenues
Segment expenses      
Research and development 2,801 3,129 12,535
General and administrative expenses 3,855 4,254 5,664
Depreciation and amortization expense 35 54
Segment loss from operations (6,656) (7,418) (18,253)
Change in fair value of warrant liability 1,786 (388) 6,868
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone 11,305
Change in fair value of put rights, net of redemptions
Loss on revaluation of digital assets
Loss on revaluation of digital asset receivables
Realized loss on sale of digital assets
Realized loss on novation of digital asset receivables
Gain on settlement with Parexel - iOx CRO 946
Loss on Registered Direct Offering (2,432)
Offering costs (662)
Impairment loss - iOx IPR&D (57,890)
Impairment loss - Tarus IPR&D (23,615)
Impairment loss - Stimunity (1,002)
Impairment loss - Saugatuck (178)
Commitment fee under Committed Purchase Agreement (839)
Gain on dissolution of investment in associate 27
Gain from sale of investment in public company 725
Impairment loss - investment in Compedica (4,804)
Loss on revaluation of investment in Compedica
Change in fair value of TON payable to settle put rights exercised
Gain on settlement of TON payable
Loss on settlement of put right liability
Foreign exchange transaction (loss) gain (5) (7) 7
Interest (expense) income, net 8 86 242
Gain on forgiveness of loan interest
Share of losses from equity method investment (44) (233)
Segment loss before benefit for income taxes (9,715) (6,781) (85,930)
Income tax benefit 3 10,548
Segment net loss $ (9,715) $ (6,778) $ (75,382)